BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 21169992)

  • 21. Practical Management of CD30⁺ Lymphoproliferative Disorders.
    Hughey LC
    Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
    Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
    Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patch/plaque mycosis-fungoides-like presentations of DUSP22-translocated T-cell lymphomas.
    Runge JS; Novice ML; Briones N; Williams K; Lowe L; Boyer DF; Wilcox RA; Tejasvi T; Hristov AC
    J Cutan Pathol; 2022 Mar; 49(3):299-305. PubMed ID: 34699105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis.
    Sarris AH; Luthra R; Papadimitracopoulou V; Waasdorp M; Dimopoulos MA; McBride JA; Cabanillas F; Duvic M; Deisseroth A; Morris SW; Pugh WC
    Blood; 1996 Sep; 88(5):1771-9. PubMed ID: 8781434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperplasia of hair follicles and other adnexal structures in cutaneous lymphoproliferative disorders: a study of 53 cases, including so-called pseudolymphomatous folliculitis and overt lymphomas.
    Kazakov DV; Belousova IE; Kacerovska D; Sima R; Vanecek T; Vazmitel M; Pizinger K; Michal M
    Am J Surg Pathol; 2008 Oct; 32(10):1468-78. PubMed ID: 18685486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphomatoid papulosis associated with mycosis fungoides: clinicopathological and molecular studies of 12 cases.
    Gallardo F; Costa C; Bellosillo B; Solé F; Estrach T; Servitje O; García-Muret MP; Barranco C; Serrano S; Pujol RM
    Acta Derm Venereol; 2004; 84(6):463-8. PubMed ID: 15844638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary Cutaneous Anaplastic Large-Cell Lymphoma With 6p25.3 Rearrangement in a Cardiac Transplant Recipient: A Case Report and Review of the Literature.
    Olson LC; Cheng E; Mathew S; Torres-Quinones M; Magro C
    Am J Dermatopathol; 2016 Jun; 38(6):461-5. PubMed ID: 26863058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
    Wood GS; Hardman DL; Boni R; Dummer R; Kim YH; Smoller BR; Takeshita M; Kikuchi M; Burg G
    Blood; 1996 Sep; 88(5):1765-70. PubMed ID: 8781433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
    Davick JJ; Mutgi KAJ; Wanat KA; Link BK; Liu V
    J Cutan Pathol; 2017 Aug; 44(8):703-712. PubMed ID: 28497585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.
    Beylot-Barry M; Lamant L; Vergier B; de Muret A; Fraitag S; Delord B; Dubus P; Vaillant L; Delaunay M; MacGrogan G; Beylot C; de Mascarel A; Delsol G; Merlio JP
    Am J Pathol; 1996 Aug; 149(2):483-92. PubMed ID: 8701987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SATB1 Defines a Subtype of Cutaneous CD30
    Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
    J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.
    Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME
    J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
    Kummer JA; Vermeer MH; Dukers D; Meijer CJ; Willemze R
    J Invest Dermatol; 1997 Nov; 109(5):636-40. PubMed ID: 9347791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Sciallis AP; Law ME; Inwards DJ; McClure RF; Macon WR; Kurtin PJ; Dogan A; Feldman AL
    Mod Pathol; 2012 Jul; 25(7):983-92. PubMed ID: 22388754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders.
    De Souza A; Tinguely M; Pfaltz M; Burghart DR; Kempf W
    J Cutan Pathol; 2014 Dec; 41(12):901-6. PubMed ID: 25353265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Associated Lymphomas and Their Risk Factors in Patients with Lymphomatoid Papulosis: A Retrospective Single-Center Study from Turkey.
    Baykal C; Kılıç Sayar S; Yazganoğlu KD; Büyükbabani N
    Turk J Haematol; 2021 Feb; 38(1):49-56. PubMed ID: 33389922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates.
    Saleh JS; Subtil A; Hristov AC
    Hum Pathol; 2023 Oct; 140():75-100. PubMed ID: 37802757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
    Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
    J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.